A recent review highlighted concerns with IV use, including rare anaphylaxis and potential hepatotoxicity (PMC narrative review)
Anal Chim Acta 794:9098 Guilbault GG (2020) Fluorescence in enzymology
In a large trial, semaglutide 2.4 mg led to about 14.9% mean body-weight loss at 68 weeks versus 2.4% with placebo
Conclusions Recent advances in this field have highlighted the importance of GST activities and the role that these enzymes play in diverse cellular processes as well as in conferring resistance to chemotherapy
Similarly research on Ipamorelin suggests a favorable profile in laboratory settings
Last reviewed: May 29, 2026 Last updated: May 29, 2026 Written by: Jay Hastings, CEO of PlexusDx Jay Hastings is the CEO of PlexusDx, a precision health company focused on genetic testing, blood biomarker insights, and personalized wellness recommendations